In summary, our findings demonstrated that ME1 promotes HCC progression by activating the NADPH-FSP1-CoQH<sub>2</sub> axis and thereby inhibiting ferroptosis, suggesting a promising therapeutic strategy for HCC treatment. The gene discussed is ME1; the disease is hepatocellular carcinoma.